Author: EvolveImmune Therapeutics

Posted Date:

April 28, 2026

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

EvolveImmune Therapeutics

April 28, 2026
EvolveImmune Therapeutics Highlights Progress for Lead Asset EVOLVE104 and EVOLVE T Cell Engager Platform in Multiple Presentations at 2026 AACR Annual Meeting

EvolveImmune Therapeutics

April 22, 2026
EvolveImmune Therapeutics to Present Update on Lead Asset EVOLVE104 and New Data for EVOLVE T Cell Engager Platform at 2026 AACR Annual Meeting

EvolveImmune Therapeutics

April 14, 2026